Apolomics Inc. (APLM)

Overview

Apollomics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel oncology therapies. Its mission is to harness the immune system and target specific molecular pathways to eliminate cancer. The company, initially founded as CBT Pharmaceuticals, Inc., underwent a name change to Apollomics, Inc. in January 2019. Since its inception in 2015, Apollomics has been at the forefront of creating innovative treatments with a primary focus on oncology, aiming to address the unmet needs in cancer care. Based in Foster City, California, Apollomics is advancing a portfolio of products that span from clinical to preclinical stages, emphasizing both the immune-oncology aspect and the molecular pathway targeting to effectively treat various cancers.

Products and Services

• Vebreltinib (APL-101)

  An oral, highly selective c-Met inhibitor currently in Phase 2 clinical trials for the treatment of non-small cell lung cancer (NSCLC). Vebreltinib is designed to target the c-Met receptor tyrosine kinase that is often aberrantly activated in many types of cancer, including NSCLC, thereby inhibiting cancer cell growth and survival.

• APL-102

  This oral, small molecule Multiple Tyrosine Kinase Inhibitor (MTKI) is in a Phase 1 clinical trial. APL-102 aims to inhibit a variety of kinases that are abnormally activated in cancer cells, representing a broad approach to targeting cancer cell proliferation and survival pathways directly.

• APL-122

  A promising tumor inhibitor candidate that targets the ErbB1/2/4 signaling pathways, currently in Phase 1 dose-escalation clinical trials. APL-122 focuses on inhibiting these signals within the brain to treat varied cancer types, aiming at a novel approach for solid tumor cancers intersecting with brain involvement.

• Uproleselan (APL-106)

  In Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory Acute Myeloid Leukemia (AML) and in a Phase 2/3 study for newly diagnosed older adults with AML. Uproleselan, targeting E-selectin, aims to address a critical survival mechanism in leukemic cells, potentially improving outcomes in a challenging patient population.

• APL-108

  A second-generation E-selective inhibitor which has completed Phase 1 clinical trials. Aimed at treating both liquid and solid cancers more effectively by targeting the E-selectin signaling pathway, which plays a role in cancer cell survival, proliferation, and metastasis.

• Preclinical Stage Immuno-oncology Product Candidates

  Includes APL-501, APL-502, APL-801, and APL-810. These preclinical stage candidates represent the company's ongoing efforts to develop next-generation immuno-oncology treatments targeting various aspects of the immune response to cancer, with the potential to either directly kill cancer cells or assist in the activation of the immune system against the tumor.